Lead Product(s) : DFP-10917
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nippon Shinyaku
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFP-10917 (radgocitabine) is a nucleoside analog delivered as a low-dose continuous infusion for the treatment of relapsed/refractory acute myeloid leukemia.
Brand Name : DFP-10917
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : DFP-10917
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nippon Shinyaku
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFP-10917 (4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride), deoxycytidine nucleoside analogue, has unique mechanism of action resulting in leukemic cell death when administered for prolonged periods at low doses.
Brand Name : DFP-10917
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 07, 2022
LOOKING FOR A SUPPLIER?